Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Sigurjonsson, Olafur Eysteinn
MetadataShow full item record
CitationConstantinescu C, Pasca S, Tat T, et al. Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?. J Immunother Cancer. 2020;8(1):e000742. doi:10.1136/jitc-2020-000742
AbstractRecently, an increasing number of novel drugs were approved in oncology and hematology. Nevertheless, pharmacology progress comes with a variety of side effects, of which cytokine release syndrome (CRS) is a potential complication of some immunotherapies that can lead to multiorgan failure if not diagnosed and treated accordingly. CRS generally occurs with therapies that lead to highly activated T cells, like chimeric antigen receptor T cells or in the case of bispecific T-cell engaging antibodies. This, in turn, leads to a proinflammatory state with subsequent organ damage. To better manage CRS there is a need for specific therapies or to repurpose strategies that are already known to be useful in similar situations. Current management strategies for CRS are represented by anticytokine directed therapies and corticosteroids. Based on its pathophysiology and the resemblance of CRS to sepsis and septic shock, as well as based on the principles of initiation of continuous renal replacement therapy (CRRT) in sepsis, we propose the rationale of using CRRT therapy as an adjunct treatment in CRS where all the other approaches have failed in controlling the clinically significant manifestations.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download
Rights© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
- Cytokine release syndrome.
- Authors: Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS
- Issue date: 2018 Jun 15
- Managing cytokine release syndrome associated with novel T cell-engaging therapies.
- Authors: Maude SL, Barrett D, Teachey DT, Grupp SA
- Issue date: 2014 Mar-Apr
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
- Authors: Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R
- Issue date: 2018 Aug
- Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.
- Authors: Khadka RH, Sakemura R, Kenderian SS, Johnson AJ
- Issue date: 2019 Jul
- Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
- Authors: Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, Appelbaum J, Maloney DG
- Issue date: 2019 Mar